Evidence map›Paper›PMID 28608311›Full record

Trial reportClinical drug investigation2017

Potential Role of Allopurinol in Preventing Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Randomized Placebo-Controlled Trial.

Zahra Ghelich Khan, Azita Hajhossein Talasaz, Hamidreza Pourhosseini, Kianoush Hosseini, Mohammad Javad Alemzadeh Ansari, Arash Jalali

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical drug investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03767322 (Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03767322 phase2unknown statusnot on this mapstarted 2018, after this paper: background citation

Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)

TypeinterventionalSponsorInstituto Nacional de Cardiologia Ignacio ChavezRan2018 to 2019Enrolled558ConditionsContrast-induced Nephropathy, Contrast-induced Acute Kidney InjuryArmsAllopurinol, Febuxostat, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Zahra Ghelich KhanClinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Azita Hajhossein TalasazSchool of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.
Hamidreza PourhosseiniTehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Kianoush HosseiniShariati Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Javad Alemzadeh AnsariRajaie Heart Center, Iran University of Medical Sciences, Tehran, Iran.
Arash JalaliTehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRIran University of Medical Sciences · IRShariati Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContrast-induced nephropathy (CIN) is a major drawback in percutaneous coronary intervention (PCI). Significant uricosuria has been reported following contrast exposure. Allopurinol-a xanthine oxidase inhibitor-has been suggested to prevent the formation of oxygen-free radicals, which may contribute to CIN. The aim of the present study was to evaluate the possible efficacy of allopurinol in preventing CIN.

methodsIn this double-blind placebo-controlled trial, patients with an estimated glomerular filtration rate ≥60 mL/min who were admitted for elective PCI, were randomized to receive either allopurinol 600 mg or a placebo administered 24 h before the procedure, and again immediately before the procedure. Blood samples were drawn at 24 h before and 24 h after contrast exposure to measure serum creatinine (SCr), uric acid, and serum cystatin-c.

resultsThe baseline characteristics were almost similar between the placebo and allopurinol groups. The overall change in SCr and the rate of CIN, which is defined as ≥25% increase in serum cystatin-c relative to baseline, failed to show a significant difference between the two groups. When adjusted on the baseline cystatin-c, SCr, sex, and positive family history, the difference in the overall increase in serum cystatin-c was statistically significantly lower in the allopurinol group.

conclusionsAllopurinol administration in patients undergoing PCI failed to show efficacy in preventing CIN. Nevertheless, this effect should be further evaluated in the patient population with chronic kidney disease.

Indexed as

AgedAllopurinolContrast MediaCreatinineDouble-Blind MethodFemaleGlomerular Filtration RateHumansKidney DiseasesMaleMiddle AgedPercutaneous Coronary InterventionAllopurinolContrast MediaCreatinine

Identifiers

PMID28608311
OpenAlexW2625610562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.